CO-RELATION OF AMYLIN AND AMYLOID FIBRILS WITH TYPE 2 DIABETES MELLITUS AND ITS ASSOCIATION WITH PRION PROTEINS AND LOW DOSE DOXYCYCLINE ROLE IN LOWERING THE GLYCEMIC INDEX - AN UNICENTRIC, DOUBLE BLINDED, RANDOMIZED CONTROLLED TRIAL

This unicentric, double-blinded randomized controlled trial investigates the correlation between amylin levels, amyloid fibril deposition, and prion protein involvement in Type 2 Diabetes Mellitus (T2DM). Amylin, co-secreted with insulin, forms toxic amyloid fibrils in pancreatic beta cells, contributing to cell dysfunction. The study explores prion-like behavior in amylin aggregation, suggesting a mechanistic link to neurodegenerative diseases. It also evaluates the therapeutic potential of low-dose doxycycline in reducing systemic inflammation and improving glycemic control. Participants aged 25–55 with T2DM will undergo biochemical assessments including serum amylin, urinary amyloid fibrils, inflammatory markers, and prion protein expression. The trial aims to identify novel biomarkers and therapeutic targets to enhance beta-cell function and glycemic regulation. Ethical protocols, informed consent, and adverse event monitoring are integral to the study. Ultimately, the research seeks to advance understanding of T2DM pathogenesis and offer innovative strategies for diagnosis and personalized treatment.